Physician profile
Arthur Itkin
NPI 1184634974
$808,347.86
in general payments reported to CMS, 2019-2025
43 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262K · 2020: $140K · 2021: $224K · 2022: $109K · 2023: $20K · 2024: $36K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Food and Beverage: $7,006 · Travel and Lodging: $4,916 · Consulting Fee: $800 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,415.00 |
| Food and Beverage | $7,006.18 |
| Travel and Lodging | $4,916.13 |
| Consulting Fee | $800.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $152,117.38 | 2019-2025 | |
| Abbvie INC. | $126,982.92 | 2019-2025 | |
| Allergan, INC. | $93,946.71 | 2019-2022 | |
| Amgen INC. | $85,661.38 | 2019-2024 | Aimovig |
| Mdd US Operations, LLC | $80,658.99 | 2019-2023 | Myobloc, Gocovri |
| Mallinckrodt Hospital Products INC. | $62,894.19 | 2020-2025 | Acthar |
| Emd Serono, INC. | $46,262.27 | 2019-2024 | Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $42,981.69 | 2020-2022 | |
| Celgene Corporation | $35,054.36 | 2019-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $32,737.03 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $20,926.63 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $12,565.38 | 2019 | |
| Biogen, INC. | $7,057.40 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Genentech USA, INC. | $5,836.60 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Supernus Pharmaceuticals, INC. | $423.66 | 2019-2023 | Qelbree |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Itkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.